Andrea Flynn | Head of Investor Relations |
Bruce Cozadd | Chairman and Chief Executive Officer |
Daniel Swisher, Jr. | President and Chief Operating Officer |
Robert Iannone | Executive Vice President, Research and Development and Chief Medical Officer |
Renée Galá | Executive Vice President and Chief Financial Officer |
Kim Sablich | Executive Vice President and General Manager, North America |
Philip Jochelson | Neuroscience Therapeutic Head |
Anne Borgman | Hematology and Oncology Therapeutic Head |
Ken Cacciatore | Cowen and Company |
Jason Gerberry | Bank of America Merrill Lynch |
Jessica Fye | J.P. Morgan |
Gary Nachman | BMO Capital Markets |
David Amsellem | Piper Sandler & Co. |
David Risinger | Morgan Stanley |
Balaji Prasad | Barclays Capital |
Marc Goodman | SVB Leerink |
Gregg Gilbert | Truist Securities |
Graig Suvannavejh | Goldman Sachs & Co. LLC |
Esther Rajavelu | UBS |
Annabel Samimy | Stifel Financial |
David Steinberg | Jefferies |
Welcome to the Jazz Pharmaceuticals plc First Quarter 2021 Earnings Conference Call.
Following an introduction from the company, we will open the call to questions. I will now turn the call over to Andrea Flynn, Head of Investor Relations at Jazz Pharmaceuticals. Thank you. Please go ahead.